Literature DB >> 20148792

How ideology shapes the evidence and the policy: what do we know about cannabis use and what should we do?

John Macleod1, Matthew Hickman.   

Abstract

In the United Kingdom, as in many places, cannabis use is considered substantially within a criminal justice rather than a public health paradigm with prevention policy embodied in the Misuse of Drugs Act. In 2002 the maximum custodial sentence tariff for cannabis possession under the Act was reduced from 5 to 2 years. Vigorous and vociferous public debate followed this decision, centred principally on the question of whether cannabis use caused schizophrenia. It was suggested that new and compelling evidence supporting this hypothesis had emerged since the re-classification decision was made, meaning that the decision should be reconsidered. The re-classification decision was reversed in 2008. We consider whether the strength of evidence on the psychological harms of cannabis has changed substantially and discuss the factors that may have influenced recent public discourse and policy decisions. We also consider evidence for other harms of cannabis use and public health implications of preventing cannabis use. We conclude that the strongest evidence of a possible causal relation between cannabis use and schizophrenia emerged more than 20 years ago and that the strength of more recent evidence may have been overstated--for a number of possible reasons. We also conclude that cannabis use is almost certainly harmful, mainly because of its intimate relation to tobacco use. The most rational policy on cannabis from a public health perspective would seem to be one able to achieve the benefit of reduced use in the population while minimizing social and other costs of the policy itself. Prohibition, whatever the sentence tariff associated with it, seems unlikely to fulfil these criteria.

Entities:  

Mesh:

Year:  2010        PMID: 20148792     DOI: 10.1111/j.1360-0443.2009.02846.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  5 in total

Review 1.  Cannabis controversies: how genetics can inform the study of comorbidity.

Authors:  Arpana Agrawal; Michael T Lynskey
Journal:  Addiction       Date:  2014-01-19       Impact factor: 6.526

2.  Societal images of Cannabis use: comparing three countries.

Authors:  John A Cunningham; Jan Blomqvist; Anja Koski-Jännes; Kirsimarja Raitasalo
Journal:  Harm Reduct J       Date:  2012-06-18

Review 3.  Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues.

Authors:  Ethan B Russo
Journal:  Front Pharmacol       Date:  2016-09-14       Impact factor: 5.810

4.  Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population.

Authors:  Suzanne H Gage; Stanley Zammit; Matthew Hickman
Journal:  F1000 Med Rep       Date:  2013-01-11

5.  Beliefs about cannabis at the time of legalization in Canada: results from a general population survey.

Authors:  John A Cunningham
Journal:  Harm Reduct J       Date:  2020-01-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.